Stock listing

NASDAQ:ETRA Electra Therapeutics, Inc. Stock

Home listing (NASDAQ) of Electra Therapeutics, Inc.

Follow Electra Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ETRA

$8.11 USD -0.32 (-3.8%)

Close on Nov 20, 2026

Past month -45.9% · daily closes, Sep 17, 2026 – Nov 20, 2026, adjusted for splits
Day range
$8.07 – $9.65 USDNov 20, 2026
Volume
376,123 sharesNov 20, 2026
Market cap
$509.8M USDAt the close on Nov 20, 2026 · price × 62.87M shares outstanding
Traded on an average day
$5.74M USDMedian day 398,089 shares · 1 day with no trades · last 3 months, Sep 17, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ETRA · Home$8.11 USD-0.32 (-3.8%)376,123$8.85$9.65$8.07$8.43Close on Nov 20, 2026

Daily closes

Last 3 months, Sep 17, 2026 – Nov 20, 2026 · NASDAQ:ETRA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.11-0.32-3.8%$8.85$9.65$8.07376,123
$8.43+0.08+1.0%$8.40$8.97$8.40323,440
$8.35+0.04+0.5%$8.43$8.97$8.09332,194
$8.31-0.53-6.0%$8.82$9.265$8.015394,876
$8.84-0.27-3.0%$9.37$9.37$7.62313,149
$9.11-0.34-3.6%$9.53$9.882$8.67545,248
$9.45+1.46+18.3%$8.25$9.485$8.18385,193
$7.99-0.23-2.8%$8.02$8.86$7.835298,184
$8.22+0.42+5.4%$7.70$8.69$7.401428,272
$7.80+0.45+6.1%$7.72$8.095$7.20401,301
$7.35-0.62-7.8%$7.95$7.99$6.97524,741
$7.97-0.10-1.2%$8.07$8.25$6.88437,028
$8.07+0.76+10.4%$7.30$8.15$7.025927,338
$7.31-0.79-9.8%$8.00$8.375$7.055385,464
$8.10-0.54-6.3%$8.385$8.48$7.945150,482
$8.64-0.34-3.8%$8.94$9.17$8.55166,475
$8.98+0.46+5.4%$8.36$9.21$8.36177,304
$8.52+0.15+1.8%$8.37$8.88$8.32176,272
$8.37-0.34-3.9%$8.98$9.175$8.26159,047
$8.71-0.54-5.8%$9.30$9.35$8.71186,453
$9.25+0.20+2.2%$9.18$9.48$9.00155,801
$9.05+0.24+2.7%$8.89$9.273$8.81126,068
$8.81+0.20+2.3%$8.75$9.17$8.71177,913
$8.61-0.14-1.6%$8.72$8.885$8.56308,987
$8.750.000.0%$8.74$9.16$8.501,380,500
$8.75-0.19-2.1%$8.97$8.99$8.58179,600
$8.94+0.33+3.8%$8.69$9.47$8.50521,000
$8.61-0.71-7.6%$9.39$9.80$8.57552,300
$9.32+0.28+3.1%$8.99$9.60$8.78346,700
$9.04-0.10-1.1%$9.13$9.30$8.68778,500
$9.14-0.02-0.2%$9.10$10.12$8.63408,000
$9.16-0.66-6.7%$9.72$9.73$8.92407,300
$9.82+0.08+0.8%$9.68$9.95$9.35276,200
$9.74-0.63-6.1%$10.46$10.46$9.28334,400
$10.37-0.31-2.9%$10.75$11.13$9.88696,600
$10.68-0.57-5.1%$11.14$11.58$10.461,255,400
$11.25-0.10-0.9%$11.37$12.09$11.23925,700
$11.35+0.03+0.3%$11.21$11.94$11.00715,600
$11.32-0.23-2.0%$11.52$11.91$11.14537,100
$11.55-0.27-2.3%$11.70$12.75$11.27438,400
$11.82-0.85-6.7%$12.54$13.56$11.71445,200
$12.67-0.95-7.0%$13.56$14.18$12.50875,400
$13.62-0.30-2.2%$13.88$14.12$13.11439,700
$13.92+0.67+5.1%$13.94$14.48$13.48813,200
$13.25-1.75-11.7%$15.00$15.50$13.255,124,319
$15.00——$15.00$15.00$15.000
Ticker
NASDAQ:ETRA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Electra Therapeutics, Inc. news

Electra Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
5 in the last 12 months · 5 in all · newest Nov 12, 2026 · oldest 2026

Where Electra Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ETRA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ETRABOATSUnited StatesUSD

Valuation

Price/book 1.3× against a median of 2.2×: 2nd lowest of 10 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$107.3M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Electra Therapeutics, Inc. · NASDAQ:ETRAUS$509.8MUS$107.3Mn/an/an/a1.3×n/a0.0×n/a
Surrozen, Inc. · NASDAQ:SRZNUS$542.5MUS$448.0Mn/a42.5×n/an/an/an/a1.64
Climb Bio, Inc. · NASDAQ:CLYMUS$539.8MUS$335.4Mn/an/an/a2.4×n/a0.0×1.44
Abbisko Cayman Limited · HKEX:2256US$518.9MUS$228.0Mn/an/an/a1.6×n/a0.2×n/a
Alumis Inc. · NASDAQ:ALMSUS$512.6MUS$116.5Mn/a16.1×n/a1.4×n/a0.1×1.58
Wave Life Sciences Ltd. · NASDAQ:WVEUS$504.9MUS$74.16Mn/a1.1×n/a1.3×−296.9%0.0×1.70
Adlai Nortye Group Ltd. · NASDAQ:ANLUS$502.2MUS$297.0Mn/a59.4×n/a2.3×−710.6%0.1×1.96
Steminent Biotherapeutics, Inc. · TPEX:7729US$496.9MUS$470.4Mn/an/an/a16.2×n/a0.0×n/a
Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575US$495.2MUS$407.1Mn/a23.2×n/a2.2×−200.8%0.0×n/a
TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872US$489.2MUS$391.6Mn/an/an/a5.0×n/a0.1×n/a
Crescent Biopharma, Inc. · NASDAQ:CBIOUS$482.9MUS$196.0Mn/a13.1×n/a1.8×−727.6%0.0×0.92
Median of the othersUS$503.5MUS$316.2M19.6×2.2×−503.7%0.0×1.61

Forecasts

5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
33.20 USD · Analysts' mean
EPS, year to Dec 2026
-6.27 · 1 analyst

Team and board

Officers

OfficerRole
Kathy DongPresident, Chief Executive Officer and Director
Chris ClarkChief Financial Officer
Gary S. KoeChief Technical Officer
Graham ParryChief Scientific Officer
Kim-Hien DaoChief Medical Officer

Board

DirectorRole
Nancy StaglianoChairperson
Adam RosenthalDirector
Beth SeidenbergDirector
Carl L. GordonDirector
Kathy DongPresident, Chief Executive Officer and Director
Matthew FustDirector
Thomas GeninattiDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−3.0%

Open Events

Financings

RaiseDate
Public offering of shares
Made bigger: US$350M · US$15 a share · Jefferies +3
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Cantor (co-lead)
Use of proceeds: To advance lead asset ipsoprubart and for other business activities, including working capital
Sep 18, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Sep 17, 2026.

Price
US$15.00 a share
Shares offered
23,333,334 shares of common stock
Offering size
US$350 million
Underwriters' option
Up to 3,500,000 more shares
Listing
ETRA on the Nasdaq Global Select Market
Underwriters
Jefferies, TD Cowen, Evercore ISI, Cantor · In the order on the cover
Shares delivered
On or about Sep 21, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJun 26, 2026
Filed publiclyAug 28, 2026
Amended onceSep 14, 2026
Declared effective by the SECSep 17, 2026
Shares registered with an exchangeSep 18, 2026
Final prospectus, with the priceSep 18, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Sep 18, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development50.4M19.3M
Selling, general and administrative11.5M7.05M
Operating income-61.9M-26.3M
Depreciation and amortization61.0K0
EBITDA-61.8M-26.3M
Interest expense1.40M0
Income before tax-62.0M-24.8M
Net income-62.0M-24.8M
Earnings per share, basic-2,113.10-0.39

Balance sheet

LineFY2025FY2024
Cash and equivalents33.0M14.8M
Short-term investments53.5M998.0K
Receivables220.0K
Current assets95.5M19.4M
Property, plant and equipment674.0K
Total assets99.4M19.4M
Accounts payable4.08M1.53M
Current liabilities9.73M4.20M
Total debt2.09M
Total liabilities11.2M122.7M
Shareholders' equity-163.4M-103.3M
Shares outstanding29.3K62.8M

Cash flow

LineFY2025FY2024
Cash from operations-60.5M-26.0M
Capital spending-733.0K0
Free cash flow-61.2M-26.0M
Cash from investing-53.0M
Cash from financing131.7M0
Change in cash18.2M3.70M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 29, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 28, 2026Big-stake noticeSEC
All 41 filings
FilingDateTypeFiled with
SCHEDULE 13D · Big-stake noticeSep 25, 2026Big-stake noticeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
S-8 · Registration statement for employee plansSep 21, 2026Offer documentSEC
8-K · Current reportSep 21, 2026Current reportSEC
424B4 · ProspectusSep 18, 2026Offer documentSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
CERT · Exchange's certificate of listingSep 18, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 18, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 18, 2026Other filingsSEC
S-1MEF · Registration of more shares for the same offeringSep 17, 2026Offer documentSEC
S-1/A · Registration statement, amendedSep 14, 2026Offer documentSEC
S-1 · Registration statementAug 28, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedAug 10, 2026Offer documentSEC
DRS · Draft registration statementJun 26, 2026Offer documentSEC
DOct 29, 2025Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Electra Therapeutics, Inc.’s releases · as of Nov 6, 2026

Common shares
62,866,792
Fully diluted
62,866,792

Fully diluted

LineSharesAs of
Common shares62,866,792Nov 6, 2026

Share count over time

CountShares
Nov 6, 202662,866,792

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Orbimed Advisors LLC6.89M11.0%US$77.5MNewNov 16, 2026
Redmile Group, LLC5.43M8.6%US$61.1MNewNov 16, 2026
EQT Fund Management S.a r.l.3.8M6.0%US$42.7MNewNov 12, 2026
Cormorant Asset Management, LP3.37M5.4%US$37.9MNewNov 16, 2026
Nextech Invest Ltd.2.64M4.2%US$29.7MNewNov 16, 2026
Blue Owl Capital Holdings LP2.61M4.2%US$29.4MNewNov 13, 2026
Sanofi2.46M3.9%US$27.7MNewNov 5, 2026
Jefferies Financial Group Inc.2.24M3.6%US$25.2MNewNov 5, 2026
JPMorgan2.1M3.3%US$23.8MNewNov 12, 2026
MIC Capital Management UK LLP1.98M3.1%US$22.2MNewNov 13, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
EcoR1 Capital, LLC1.7M2.7%US$19.1MNewNov 16, 2026
Farallon Capital Management, L.L.C.1.7M2.7%US$19.1MNewNov 16, 2026
Ra Capital Management, L.P.1.69M2.7%US$19MNewNov 16, 2026
AllianceBernstein1.52M2.4%US$17.1MNewNov 16, 2026
Balyasny Asset Management L.P.1.19M1.9%US$13.4MNewNov 16, 2026
Hood River Capital Management LLC1.11M1.8%US$12.5MNewNov 16, 2026
Logos Global Management LP1M1.6%US$11.3MNewNov 19, 2026
Jennison Associates LLC923K1.5%US$10.4MNewNov 13, 2026
Braidwell LP906K1.4%US$10.2MNewNov 16, 2026
T. Rowe Price711K1.1%US$8MNewNov 16, 2026
Deerfield Management Company, L.P.700K1.1%US$7.88MNewNov 16, 2026
Seven Grand Managers, LLC540K0.86%US$6.08MNewNov 16, 2026
Boxer Capital Management, LLC450K0.72%US$5.06MNewNov 16, 2026
Millennium368K0.59%US$4.14MNewNov 16, 2026
Woodline Partners LP361K0.57%US$4.06MNewNov 16, 2026
Soleus Capital Management, L.P.250K0.40%US$2.81MNewNov 16, 2026
Vanguard245K0.39%US$2.76MNewNov 13, 2026
Integral Health Asset Management, LLC200K0.32%US$2.25MNewNov 16, 2026
Maven Securities LTD200K0.32%US$2.25MNewNov 13, 2026
Victory Capital178K0.28%US$2MNewNov 10, 2026
Ensign Peak Advisors, Inc158K0.25%US$1.78MNewNov 12, 2026
Citadel146K0.23%US$1.64MNewNov 16, 2026
Goldman Sachs130K0.21%US$1.46MNewNov 16, 2026
Ameriprise128K0.20%US$1.44MNewNov 16, 2026
Monashee Investment Management LLC100K0.16%US$1.13MNewNov 6, 2026
Soros Fund Management LLC75,0000.12%US$844KNewNov 13, 2026
Hrt Financial LP70,2400.11%US$790KNewNov 13, 2026
Ghisallo Capital Management LLC70,0000.11%US$788KNewNov 19, 2026
Jane Street59,7520.10%US$672KNewNov 12, 2026
Point72 Asset Management, L.P.47,0050.07%US$529KNewNov 16, 2026
Squarepoint Ops LLC43,7680.07%US$492KNewNov 9, 2026
ExodusPoint Capital Management, LP30,5930.05%US$344KNewNov 16, 2026
Jump Financial, LLC26,3990.04%US$297KNewNov 13, 2026
Longaeva Partners L.P.25,0000.04%US$281KNewNov 16, 2026
Diametric Capital, LP24,8490.04%US$280KNewNov 16, 2026
Y-Intercept (Hong Kong) Ltd21,1030.03%US$237KNewOct 16, 2026
Quantbot Technologies LP20,5110.03%US$231KNewNov 12, 2026
Shay Capital LLC20,0300.03%US$225KNewNov 16, 2026
Federated Hermes, Inc.15,7000.02%US$177KNewNov 12, 2026
Two Sigma15,0000.02%US$169KNewNov 16, 2026

This page holds 50 of 56 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Orbimed Advisors LLC
Director, 10% owner
Buy20,700USD 8.45US$175KNov 10, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy2,000USD 8.45US$16,900Nov 10, 2026
Gordon Carl L
Director, 10% owner
Buy20,700USD 8.45US$175KNov 10, 2026
Gordon Carl L
Director, 10% owner
Buy2,000USD 8.45US$16,900Nov 10, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy4,000USD 8.24US$32,960Nov 9, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy16,000USD 8.24US$132KNov 9, 2026
Gordon Carl L
Director, 10% owner
Buy4,000USD 8.24US$32,960Nov 9, 2026
Gordon Carl L
Director, 10% owner
Buy16,000USD 8.24US$132KNov 9, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy9,816USD 7.85US$77,056Nov 6, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy39,600USD 7.85US$311KNov 6, 2026
All 36 trades
InsiderTradeSharesPriceValueDate
Gordon Carl L
Director, 10% owner
Buy9,816USD 7.85US$77,056Nov 6, 2026
Gordon Carl L
Director, 10% owner
Buy39,600USD 7.85US$311KNov 6, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy125,200USD 7.31US$915KNov 5, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy30,891USD 7.31US$226KNov 5, 2026
Gordon Carl L
Director, 10% owner
Buy125,200USD 7.31US$915KNov 5, 2026
Gordon Carl L
Director, 10% owner
Buy30,891USD 7.31US$226KNov 5, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy9,267USD 7.78US$72,097Nov 4, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy37,100USD 7.78US$289KNov 4, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy5,000USD 7.07US$35,350Nov 4, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy20,000USD 7.07US$141KNov 4, 2026
Gordon Carl L
Director, 10% owner
Buy9,267USD 7.78US$72,097Nov 4, 2026
Gordon Carl L
Director, 10% owner
Buy37,100USD 7.78US$289KNov 4, 2026
Gordon Carl L
Director, 10% owner
Buy5,000USD 7.07US$35,350Nov 4, 2026
Gordon Carl L
Director, 10% owner
Buy20,000USD 7.07US$141KNov 4, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy24,313USD 7.84US$191KNov 3, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy97,800USD 7.84US$767KNov 3, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy24,400USD 7.88US$192KNov 3, 2026
Orbimed Advisors LLC
Director, 10% owner
Buy98,600USD 7.88US$777KNov 3, 2026
Gordon Carl L
Director, 10% owner
Buy24,313USD 7.84US$191KNov 3, 2026
Gordon Carl L
Director, 10% owner
Buy97,800USD 7.84US$767KNov 3, 2026
Gordon Carl L
Director, 10% owner
Buy24,400USD 7.88US$192KNov 3, 2026
Gordon Carl L
Director, 10% owner
Buy98,600USD 7.88US$777KNov 3, 2026
OrbiMed Capital GP VII LLC
Director, 10% owner
Buy333,333USD 15.00US$5MSep 21, 2026
OrbiMed Capital GP VII LLC
Director, 10% owner
Buy1,000,000USD 15.00US$15MSep 21, 2026
Gordon Carl L
Director, 10% owner
Buy333,333USD 15.00US$5MSep 21, 2026
Gordon Carl L
Director, 10% owner
Buy1,000,000USD 15.00US$15MSep 21, 2026

Big stakes

HolderStakeSharesDate
Orbimed Advisors LLC11.00%6.89MSep 21, 2026
Dr. Beth C. Seidenberg10.10%6.35MSep 30, 2026
Redmile Group, LLC8.70%5.46MSep 21, 2026
LSP 7 Cooperatief U.A.6.00%3.8MSep 21, 2026
Cormorant Asset Management, LP5.36%3.37MSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Director · Since at least Sep 18, 2026
Matthew Fust
Other companies: Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Crinetics Pharmaceuticals, Inc. (Director · Since at least Jul 17, 2018); Atara Biotherapeutics, Inc. (Director, Audit Committee Chair · Since at least Oct 15, 2014); Ultragenyx Pharmaceutical Inc. (Director · Since at least Jan 30, 2014); MacroGenics, Inc. (Director · Mar 5, 2014 – May 16, 2019 · Past); Sunesis Pharmaceuticals Inc (Director · Jun 28, 2013 – Jun 30, 2016 · Past); Onyx Pharmaceuticals Inc (EVP & Chief Financial Officer · Jan 5, 2009 – Oct 1, 2013 · Past); Jazz Pharmaceuticals plc (EVP, Chief Financial Officer · May 31, 2007 – Nov 28, 2008 · Past)
Director · Since at least Sep 18, 2026
Nancy Stagliano
Other companies: Pandion Therapeutics Inc (Director · Jul 16, 2020 – Apr 1, 2021 · Past)
Chairperson · Since at least Sep 18, 2026
Adam RosenthalDirector · Since at least Nov 5, 2026
Beth SeidenbergDirector · Since at least Nov 4, 2026
Chris ClarkChief Financial Officer · Since at least Nov 4, 2026
Christopher William ClarkChief Financial Officer · Since at least Sep 18, 2026
David J TuckerPrincipal Accounting Officer · Since at least Sep 18, 2026
Gary S. KoeChief Technical Officer · Since at least Sep 18, 2026
Graham ParryChief Scientific Officer · Since at least Sep 18, 2026
All 14 people
PersonSeat
Kathy DongPresident, Chief Executive Officer and Director · Since at least Nov 4, 2026
Kim-Hien DaoChief Medical Officer · Since at least Sep 18, 2026
Quehuong DongPresident & CEO, Director · Since at least Sep 18, 2026
Thomas GeninattiDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Electra Therapeutics, Inc.